Cargando…

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors

Detalles Bibliográficos
Autores principales:	Smith, C. I. Edvard, Brown, Jennifer R., Zain, Rula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650313/ https://www.ncbi.nlm.nih.gov/pubmed/34887877 http://dx.doi.org/10.3389/fimmu.2021.804735

Ejemplares similares

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
por: Weber, Alexander N. R., et al.
Publicado: (2017)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation
por: Roman-Garcia, Sara, et al.
Publicado: (2018)

Novel Bruton’s tyrosine kinase inhibitors currently in development
por: D’Cruz, Osmond J, et al.
Publicado: (2013)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Khan, Abdullah Mohammad
Publicado: (2022)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Ababneh, Obada, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2023)

Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis
por: Shulga, Olga, et al.
Publicado: (2023)

Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia
por: Naylor-Adamson, Leigh, et al.
Publicado: (2021)

The Use of Bruton’s Tyrosine Kinase Inhibitors to Treat Allergic Disorders
por: Dispenza, Melanie C.
Publicado: (2021)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
por: Lorenzo-Vizcaya, Ana, et al.
Publicado: (2020)

Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice
por: O'Riordan, Caroline E., et al.
Publicado: (2019)

Bruton’s Tyrosine Kinase Supports Gut Mucosal Immunity and Commensal Microbiome Recognition in Autoimmune Arthritis
por: Bonami, Rachel H., et al.
Publicado: (2022)

Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
por: Ringheim, Garth E., et al.
Publicado: (2021)

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies
por: Moore, Donald C., et al.
Publicado: (2021)

Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy
por: Ni, Ying, et al.
Publicado: (2022)

Targeting Multiple End Organs in Lupus and Other Systemic Rheumatic Diseases by Inhibiting Bruton’s Tyrosine Kinase
por: Du, Yong, et al.
Publicado: (2022)

Expression of Bruton´s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination
por: Elkjaer, Maria L., et al.
Publicado: (2023)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021)

The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia
por: Gordon, Max J., et al.
Publicado: (2021)

Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
por: von Hundelshausen, Philipp, et al.
Publicado: (2021)

Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor
por: Turetsky, Anna, et al.
Publicado: (2014)

Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies
por: Campbell, Robert, et al.
Publicado: (2018)

Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors
por: Naik, Piyu Parth
Publicado: (2022)

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
por: Wen, Tingyu, et al.
Publicado: (2020)

All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: No
por: Rotstein, Dalia L
Publicado: (2022)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
por: Wang, Xianhui, et al.
Publicado: (2021)

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase
por: Ma, Hong, et al.
Publicado: (2013)

Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
por: Schneider, Raphael, et al.
Publicado: (2022)

Bruton’s Tyrosine Kinase-Mediated Signaling in Myeloid Cells Is Required for Protective Innate Immunity During Pneumococcal Pneumonia
por: de Porto, Alexander P., et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase, a Component of B Cell Signaling Pathways, Has Multiple Roles in the Pathogenesis of Lupus
por: Satterthwaite, Anne B.
Publicado: (2018)

Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
por: Montoya, Skye, et al.
Publicado: (2023)

X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure
por: O'Riordan, Caroline E., et al.
Publicado: (2020)

Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B‐cell receptor signaling in mice
por: Rip, Jasper, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis
por: Arneson, Laura C, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy
por: García-Merino, Antonio
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gtu1atmc2cs84kh33at1nq45hf